Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.

Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW.

Blood. 2012 Sep 27;120(13):2658-68. Epub 2012 Aug 13.

PMID:
22889761
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.

Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller J, Fruehauf S.

Leuk Lymphoma. 2009 Oct;50(10):1676-86. doi: 10.1080/10428190903150847.

PMID:
19657955
[PubMed - indexed for MEDLINE]
3.

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S.

Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5. Epub 2006 Oct 31.

PMID:
17077147
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.

Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.

Clin Cancer Res. 2006 Oct 1;12(19):5869-78.

PMID:
17020995
[PubMed - indexed for MEDLINE]
Free Article
5.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

PMID:
19240172
[PubMed - indexed for MEDLINE]
Free Article
6.

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, Bronson R, Ghobrial IM, Griffin JD.

Leukemia. 2012 May;26(5):985-90. doi: 10.1038/leu.2011.360. Epub 2011 Dec 20.

PMID:
22182920
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.

Tabe Y, Jin L, Iwabuchi K, Wang RY, Ichikawa N, Miida T, Cortes J, Andreeff M, Konopleva M.

Leukemia. 2012 May;26(5):883-92. doi: 10.1038/leu.2011.291. Epub 2011 Oct 18.

PMID:
22005789
[PubMed - indexed for MEDLINE]
8.

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, Valent P.

Cancer Res. 2010 Feb 15;70(4):1513-23. doi: 10.1158/0008-5472.CAN-09-2181. Epub 2010 Feb 9.

PMID:
20145140
[PubMed - indexed for MEDLINE]
Free Article
9.

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.

Wongboonma W, Thongnoppakhun W, Auewarakul CU.

Exp Mol Pathol. 2012 Apr;92(2):259-65. doi: 10.1016/j.yexmp.2012.01.007. Epub 2012 Jan 31.

PMID:
22314255
[PubMed - indexed for MEDLINE]
10.

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

Wolff NC, Ilaria RL Jr.

Blood. 2001 Nov 1;98(9):2808-16.

PMID:
11675355
[PubMed - indexed for MEDLINE]
Free Article
11.

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr.

Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.

PMID:
15657179
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.

Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL, Jiang X.

J Natl Cancer Inst. 2013 Mar 20;105(6):405-23. doi: 10.1093/jnci/djt006. Epub 2013 Feb 27.

PMID:
23446755
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.

Simara P, Stejskal S, Koutna I, Potesil D, Tesarova L, Potesilova M, Zdrahal Z, Mayer J.

Am J Hematol. 2013 May;88(5):385-93. doi: 10.1002/ajh.23419. Epub 2013 Mar 27.

PMID:
23420553
[PubMed - indexed for MEDLINE]
14.
15.

Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.

Härtel N, Klag T, Hanfstein B, Mueller MC, Schenk T, Erben P, Hochhaus A, La Rosée P.

J Cancer Res Clin Oncol. 2012 Feb;138(2):203-12. doi: 10.1007/s00432-011-1086-x. Epub 2011 Nov 17.

PMID:
22089930
[PubMed - indexed for MEDLINE]
16.

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.

Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M.

Mol Cancer Ther. 2008 Jan;7(1):48-58. doi: 10.1158/1535-7163.MCT-07-0042.

PMID:
18202009
[PubMed - indexed for MEDLINE]
Free Article
17.

Loss of response to imatinib: mechanisms and management.

Shah NP.

Hematology Am Soc Hematol Educ Program. 2005:183-7.

PMID:
16304378
[PubMed - indexed for MEDLINE]
Free Article
18.

Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.

Rapozzi V, Cogoi S, Xodo LE.

Mol Cancer Ther. 2006 Jul;5(7):1683-92.

PMID:
16891454
[PubMed - indexed for MEDLINE]
Free Article
19.

Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.

Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K, Flefleh C, Castaneda S, Inigo I, Kan D, Wen ML, Kramer R, Blackwood-Chirchir A, Lee FY.

Clin Cancer Res. 2006 Dec 1;12(23):7180-6.

PMID:
17145844
[PubMed - indexed for MEDLINE]
Free Article
20.

Overcoming kinase resistance in chronic myeloid leukemia.

Lee F, Fandi A, Voi M.

Int J Biochem Cell Biol. 2008;40(3):334-43. Review.

PMID:
18401881
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk